Ability to detect CAD confirmed for PET with novel radiotracer

Confirming a previous report, PET with a novel radiotracer had good sensitivity and specificity for CAD detection and outperformed single-photon emission CT myocardial perfusion imaging.
As Healio previously reported, in the phase 3 AURORA trial presented at the Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology in 2022, the PET system, which includes the radiotracer 18F flurpiridaz (GE Healthcare/Lantheus Medical Imaging), exceeded the performance goal of 60% sensitivity and specificity, meaning the lower bound of the 95% CI needed to be more than 60%.

Confirming a previous report, PET with a novel radiotracer had good sensitivity and specificity for CAD detection and outperformed single-photon emission CT myocardial perfusion imaging.
As Healio previously reported, in the phase 3 AURORA trial presented at the Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology in 2022, the PET system, which includes the radiotracer 18F flurpiridaz (GE Healthcare/Lantheus Medical Imaging), exceeded the performance goal of 60% sensitivity and specificity, meaning the lower bound of the 95% CI needed to be more than 60%.